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Abstract 
Markov influence diagrams (MIDs) are a new type of probabilistic graphical models that extend 
influence diagrams in the same way as Markov decision trees extend decision trees. They have 
been designed to build state-transition models, mainly in medicine, and perform cost-
effectiveness analysis. Using a causal graph that may contain several variables per cycle, MIDs 
can model various features of the patient without multiplying the number of states; in particular, 
they can represent the history of the patient without using tunnel states. OpenMarkov, an open-
source tool, allows the decision analyst to build and evaluate MIDs²including cost-
effectiveness analysis and several types of deterministic and probabilistic sensitivity analysis²
with a graphical user interface, without writing any code. This way, MIDs can be used to easily 
build and evaluate complex models whose implementation as spreadsheets or decision trees 
would be cumbersome or unfeasible in practice. Furthermore, many problems that previously 
required discrete event simulation can be solved with MIDs, i.e., within the paradigm of state-
transition models, in which many health economists feel more comfortable.  
1 Introduction 
Several types of computational models are available for medical decision making. Decision 
trees1 are the most popular, but they are suitable only for small problems because their size 
grows exponentially with the number of decisions and chance variables.  
A probabilistic graphical model (PGM) consists of a set of variables, a graph in which every 
node represents a variable, a set of probability distributions and, in some cases, value functions. 
Those probabilities represent a joint conditional probability distribution that satisfies some 
properties of independence²for example, the assumption that the results of two tests are 
conditionally independent both in the presence and in the absence of a disease²dictated by the 
graph.  
Influence diagrams (IDs)2 are a particular type of PGM that, like decision trees, contain three 
types of nodes: chance, decision and value. The main difference is that the graph of the ID is 
usually causal and each variable (for example, a decision or the result of a test) is represented 
only once, while in a decision tree there are usually several nodes representing each variable in 
different scenarios. IDs have the advantages of being very compact and representing 
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probabilistic independencies. These advantages make it easier to build and maintain large 
decision models.  
Cost-effectiveness analysis (CEA) with decision trees is complicated in problems that involve 
several decisions. Noticeably, embedded decision nodes²i.e., those that are not the root of the 
tree²may lead to wrong results.3 Having only one decision node (at the root of the tree) 
representing all the possible strategies, as recommended by Kuntz and Weinstein,4 usually leads 
to huge decision trees even for small problems.3,5 An algorithm proposed recently can perform 
CEA on trees with embedded decision nodes,5 but still the size of problems that can be 
represented is very limited. In contrast, IDs can solve very complex problems: using an adapted 
version of that algorithm, we could perform CEA on two IDs whose equivalent decision trees 
would contain millions of branches.6 
CEA is even more difficult when time must be modelled explicitly. The most common approach 
is to build state-transition models,7-9 which allocate members of a population into one of several 
categories, or health states, and discretise time into a set of fixed length intervals, called cycles, 
such that transitions between states can occur only at a certain moment in every cycle. Markov 
decision trees, originally called Markov cycle trees,10 were the first representation used to 
implement state-transition models; other implementations use spreadsheets, discrete event 
simulation or computer programs, usually written in C++, R or BUGS;11 each approach has pros 
and cons, as we discuss in Section 4. 
In this paper we introduce Markov influence diagrams (MID) as an extension of IDs, in the 
same way as Markov decision trees extend decision trees. The main difference is that IDs only 
contain atemporal variables²IRUH[DPSOHWKHSDWLHQWV¶JHQGHU²while MIDs also contain 
temporal variables, whose value evolves over time²for example, the age or the health state.  
Due to the computational cost, MIDs containing temporal decisions can only be evaluated for 
very short horizons, as explained below. For this reason we will assume that all decisions are 
atemporal, i.e., they are made at the beginning of the process; they may be conditioned on future 
events IRUH[DPSOH³GRWKHWHVWZKHQWKHV\PSWRPLVSUHVHQW´, but the policy is the same for 
all cycles. This way it is possible to evaluate MIDs with large horizons. To our knowledge, this 
restriction to atemporal decisions is also present in all models for CEA, including cohort 
models, patient-level simulation and discrete event simulation. An important difference, 
however, is that cohort models usually represented WKHSDWLHQW¶Vstate with a single variable, 
taking on a limited number of values (states), and consequently often need to multiply the 
number of states²for example, to represent the patient history²while patient-level simulation, 
discrete event simulation and MIDs can use several variables to model different features of the 
health state. The main difference of IDs and MIDs with respect to the other types of models for 
CEA is the explicit use of a causal graph that represents all the variables and the relations 
among them. This graph facilitates the construction, debugging and maintenance of the model 
and the communication with experts²for example, with health technology assessment 
agencies. 
Several example MIDs for medical problems are available on the Internet.a They were built with 
OpenMarkov,b an open-source software package for MIDs that enables the user to perform cost-
                                                     
a
 See www.probmodelxml.org/networks.  
b
 www.openmarkov.org.  
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effectiveness analysis and several types of sensitivity analysis with a graphical user interface, 
without writing any code. 
2 Definition of MID 
An MID, like any other PGM, consists of a graph and a set of potentials. The graph depicts the 
causal relations between the variables, while the potentials encode the numerical parameters. In 
this section we describe both elements of MIDs using as an example a model designed by 
Chancellor et al.12 to compare the cost-effectiveness of two anti-HIV therapies: lamivudine plus 
zidovudine (combination therapy) vs. zidovudine alone (monotherapy). These therapies are now 
obsolete, but the model is still useful for didactic purposes.c  
In this model the clinical condition of the patient is described by four possible states.  State A, 
the least severe disease state, means that the CD4 count is between 200 and 500 cells/mm3. 
State B means less than 200 cells/mm3. State C represents AIDS and the final state, D, 
represents death. The possible transitions are depicted as arrows in Figure 1. The cycle length is 
one year. The effectiveness is measured as life duration, without taking into account the quality 
of life. 
 
Figure 1. Transition diagram for the HIV model.12 
2.1 Qualitative information: structure of the model 
A graph consists of nodes and links. MIDs, like decision trees and influence diagrams, have 
three types of nodes: decision, chance and value. If a node represents the value in the i-th cycle 
of a temporal variable, we write i between square brackets, as in Figure 2. 
                                                     
c
 An Excel version of this model can be found on the web site for the book by Briggs et al.7: 
www.herc.ox.ac.uk/downloads/supporting-material-for-decision-modelling-for-health-economic-
evaluation/ex47sol.xls.  
 
State A: 200 < cd4 < 500 cells/mm3 
State C: AIDS 
State B: cd4 < 200 cells/mm3 State D: dead 
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Figure 2. The first two cycles of an MID for the HIV example. 
Decision nodes represent choices available to the decision maker. They are drawn as rectangles. 
In Figure 2, the decision node Therapy choice represents the selection of one of the two 
therapies under evaluation. This node has no index because, as said above, we assume that all 
the decisions are atemporal. 
Chance nodes, drawn as rounded rectangles, represent all the properties that are not under the 
GHFLVLRQPDNHU¶VFRQWUROIn medical PGMs, they UHSUHVHQWWKHSDWLHQW¶VIHDWXUHVVXFKDs sex, 
age and health condition at a certain moment.d Figure 2 contains 7 chance variables. State [0] 
represents the state of the patient in cycle 0 (start of therapy), with four values, one for each 
health state: A, B, C and D. State [1] represents the state of the patient in cycle 1 (one year 
later) and has the same domain as State [0]. Time in treatment [0] and Time in treatment [1] are 
numeric variables that represent, for each cycle, how much time the patient has been receiving 
treatment. Therapy applied [i] represents the therapy applied in the i-th cycle, which can be 
combination therapy, monotherapy or, if the patient is dead, none. Transition inhibited [1] 
indicates whether the addition of lamivudine has prevented a transition that would have 
occurred if the patient had received zidovudine (AZT) alone. 
Value nodes represent the decision mDNHU¶VSD\RIIVVXFKDVFRVWVDQGKHDOWKRXWFRPHV They 
are drawn as hexagons. In Figure 2, Life years [0] and Life years [1] represent effectiveness, 
while the other value nodes represent economic costs. 
Nodes in an MID are connected by directed links. When there is a link ܺ ՜ ܻ, we say that ܺ is 
a parent of ܻ. These links usually denote causal influence. For example, Therapy applied [i] 
depends on Therapy choice, on State [i] (because dead patients do not receive any therapy) and 
on Time in treatment [i] (because combination therapy is applied for a maximum of two years 
and then all patients receive monotherapy). State [1] depends on State [0] and on whether the 
transition has been inhibited. The effectiveness (Life years [i]), the direct medical costs and the 
community care costs depend on the current state, while the cost of drugs depends on the 
therapy applied.  
                                                     
d
 7KLV LV D GLIIHUHQFH ZLWK GHFLVLRQ WUHHV ZKLFK GR QRW UHSUHVHQW SDWLHQWV¶ EDVHOLQH FKDUDFWHULVWLFV IRU
example, sex and age) as nodes, but as parameters of the model. 
 5 
 
2.2 Quantitative information: numerical parameters 
An MID, like any other PGM for decision analysis, contains two types of numeric parameters: 
probabilities and values. Each chance or value node has an associated potential, i.e., a function 
that assigns a real number to each configuration of a set of variables. The potential for a chance 
node is a probability distribution for that variable conditioned on its parents in the graph. The 
potential for a value node is a function that indicates how this value depends on its parents.  
A potential defined on a set of n discrete variables can be encoded as an n-dimensional table. (In 
this context, discrete is synonymous of categorical or finite-states. A numeric variable can be 
discretised by defining a finite set of intervals.) In our example, the probability distribution for 
node State [0], which has no parents in the graph, depends on no variable, i.e., it is the a priori 
probability P(State [0]). In a cohort interpretation of the model, this probability represents the 
proportion of individuals in each state at the beginning of the treatment. As this variable has 4 
states, the probability can be represented by a one-dimensional matrix (a vector) of 4 non-
negative numbers, whose sum must be 1. The assumption that all the patients are initially in 
state A is encoded by setting the probability to 1 for this state and 0 for the others.  
The probability of State [1] conditioned on its parents, State [0] and Transition inhibited [1], 
can be represented by a three-dimensional matrix, as shown in Figure 3.  
 
Figure 3. Probability table for State [1], conditioned on State [0] and Transition inhibited [1]. The 
leftmost column lists the parents of State [1] and the four possible values of this variable. When the 
transition has been inhibited, the patient remains in the same state as in the previous cycle. A red triangle 
denotes second-order uncertainty; in this example there are three columns having each an associated 
Dirichlet distribution, which can be edited in a specific dialog. 
The potential for Therapy applied [0], i.e., the probability P(Therapy applied [0] | State [0], 
Therapy choice, Time in treatment [0]) cannot be represented as a table because Time in 
treatment [0] is a numeric variable. It can be represented as the tree in Figure 4, which in this 
particular case does not contain any numeric information because the therapy applied depends 
deterministically on the three parents of this variable.  
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Figure 4. A tree for P(Therapy applied [0] | State [0], Therapy choice, Time in treatment [0]). Even if the 
WKHUDS\FKRLFHLV³FRPELQDWLRQWKHUDS\´WKHWUHDWPHQWUHYHUWVWRPRQRWKHUDS\DIWHUWKHWZRILUVWF\FOHV 
The probability distribution for Time in treatment [0] is a Dirac delta because we know with 
certainty that the value of this variable is 0.  Time in treatment [1] depends deterministically on 
its only parent, Time in treatment [0]; these two variables are related by a potential of type 
³F\FOHOHQJWKVKLIW´VRWKDWWKHYDlue of Time in treatment [1] is the value of Time in 
treatment [0] plus the cycle length. 
The variable Transition inhibited [1] represents the effect of combination therapy, which in 
&KDQFHOORU¶V model reduces the transition rate independently of the state of departure. Its 
probability is also represented by a table.  
In the same way as every chance node has an associated conditional probability, every value 
node has a function that indicates how that value (the effectiveness or the cost) depends on its 
parents in the graph. In our example these functions can be represented by tables because they 
are all defined on discrete variables.  
3 Building MIDs in practice 
3.1 The process of building MIDs 
An MID can be built by first drawing it on paper and then implementing it in a general 
programming language, such as C++, R or MATLAB. However, it is much easier to build it 
using a dedicated software package, such as OpenMarkov, because its graphical user interface 
facilitates the construction of the graph and the encoding of the potentials and because this tool 
offers efficient evaluation algorithms, as explained below.  
The first step in the construction of an MID is selecting the variables and assigning a domain to 
each decision and each chance variable. The next one is to draw links among the 
nodes/variables, as explained in Section 2.1. Figure 5 and 6 show two MIDs containing two 
decisions (one about a test and one about a treatment) and several chance nodes that represent 
WKHSDWLHQW¶VSHUVRQDOFKDUDFWHULVWLFVWKHKHDOWKVWDWHVeveral symptoms, test results and 
therapies, and the possibility of healing as a consequence of a treatment.  It also contains several 
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value nodes that represent effectiveness (quality of life) and economic costs. Please note that all 
the links represent either causality or functional dependence. 
 
Figure 5. An MID for analysing the cost-effectiveness of the HPV vaccine, based on Callejo et al.13 
 
Figure 6.  An MID for the diagnosis of coronary heart disease, based on Walker et al.14 
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The last step, the most difficult one, consists of assigning the potentials, especially those that 
contain numeric parameters. In Section 2.2 we have mentioned three types of potentials: table, 
tree and cycle length shift. There are two technical reports15,16 that describe in detail these and 
other types of relations and may serve as a guide for selecting the most appropriate 
representation for each potential depending on the type of variables involved, on the data 
available and, sometimes, RQWKHPRGHOOHU¶VSUHIHUHQFHV 
2SHQ0DUNRY¶VWXWRULDO(www.openmarkov.org/docs/tutorial) DQG3URE0RGHO;0/¶VZHEVLWH 
(www.probmodelxml.org/networks) contain several examples that may be useful for both 
beginners and advanced modellers. 
3.2 Rǯ in MIDs 
This section illustrates with two examples the use of memory variables in MIDs to represent the 
SDWLHQW¶VKLVWRU\ZLWKRXWPXOWLSO\LQJWKHQXPEHURIVWDWHV 
3.2.1 First example: Duration of stay in a certain state 
In some medical problems the transition probabilities depend on how long the patient has been 
in a certain state. For example, the longer an HIV patient has had a low CD4 count (state B), the 
higher the probability of developing AIDS (state C) or dying (state D). 7KHUHIRUH&KDQFHOORU¶V
model can be refined by subdividing state B into three sub-states: B1, B2 and B3, such that B1 
means that the patient has just entered state B, B2 that he entered state B in the previous cycle 
and B3 that he has been in state B for at least two cycles. States B1 to B3 are called tunnel 
states because they can be visited only in a fixed sequence,10 as shown in Figure 7.  
 
Figure 7. A refined transition diagram for the HIV model (compare it with Figure 1). Sub-states B1, B2 
and B3, called tunnel states because they can be visited only in a fixed sequence, indicate how long the 
patient has been in state B.  
An alternative to using tunnel states is to represent the ³state´ with two variables: one for the 
clinical state²with four possible states: A, B, C and D, as in the original model²and another 
one for indicating how long the patient has been in the current state, as shown in Figure 8. The 
auxiliary variable State change [1] tracks whether there has been a transition in cycle 1. The 
link from Time in current state [0] to State [1] means that when the patient is in state B, the 
State A
State B1
State B3
State B2 State DState C
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transition probabilities to C and to D do not only depend on Therapy choice, but also on the 
time spent in B. 
  
Figure 8. A refinement of the MID in Figure 2. The transition probabilities between State [0] and 
State [1] now depend on how many cycles the patient has spent in the current state. By definition, Time in 
current state [0] = 0. If State [1] takes the same value as State [0] , then State change [1] = false and Time 
in current state [1] = Time in current state [0]  + 1; otherwise, State change [1]  = true and Time in 
current state [1] is reset to 0. 
The variables that summarise the history of the patient, such as Time in treatment [i] and Time 
in current state [i], are called memory variables. This way the transition probabilities may 
depend on the past without (explicitly) multiplying the number of states. Therefore, if State [i] 
has 4 values, Time in treatment [i]  has m values and Time in current state [i] has n, this MID is 
equivalent to having 4·m·n states, but its construction and maintenance is much easier than 
building a traditional model with lots of states, because the user does not need to think of all the 
possible combinations of the variables WKDWMRLQWO\UHSUHVHQWWKHSDWLHQW¶V³VWDWH´.  
3.2.2 Second example: Modelling relapses 
In some cases the transition probabilities depend on the SDWLHQW¶VHQWLUH history. For example, a 
more up-to-date model for HIV should allow backward transitions from state C (AIDS) to A or 
B, due to the efficacy of modern treatments; the probabilities of these transitions depend on how 
many times the patient has had AIDS. 
As in the previous example, this problem might be modelled by multiplying the number of 
states, such that they do not only represent the current health condition, but also the number of 
relapses, as shown in Figure 9. 
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Figure 9. An alternative refinement of the HIV model that includes backward transitions. The subindex of 
a state indicates the number of relapses, i.e., the number of times the patient has entered state C; 
subindex 2 means that the patient has had AIDS at least twice. 
An alternative approach would be to have one variable representing the clinical state and 
another one representing the number of relapses, as in Figure 10. 
 
Figure 10.  An MID accounting for the number of relapses in AIDS. When the patient transitions from 
states A or B into C, Enter in AIDS takes the value true and Number of relapses [1] = Number of 
relapses [0] + 1; otherwise Enter in AIDS = false and Number of relapses [1]  = Number of relapses [0]. 
The transition probabilities from State [0] to State [1] depend on Time in treatment [0] and on Number of 
relapses [0]. 
4 Algorithms for MIDs 
An MID can be converted into an ordinary ID by expanding it to the desired horizon and then 
evaluated with the standard algorithms for IDs. For example, an MID containing only discrete 
variables²and numeric variables whose value is known with certainty, as in the HIV model²
can be evaluated with the algorithm by Arias and Díez,6 which computes the incremental cost-
D
A0 A1 A2
C0 C1 C2
B0 B1 B2
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effectiveness ratios (ICERs) and the optimal strategy for each value of the willingness-to-pay.e 
If the MID has only one decision, this algorithm performs essentially the same operations as 
cohort evaluation, but it can also evaluate models containing several decisions, such as the 
examples in Figure 5 and 6. However, some MIDs having numerical variables may require 
patient-level simulation. 
Similarly, it is possible to use variable elimination, a well-known algorithm for Bayesian 
networks and influence diagrams,17 to compute and display graphically the temporal evolution 
of a variable, as shown in see Figure 11. It is also possible to modify the parameters of the 
model and perform the same types of deterministic and probabilistic sensitivity analysis as with 
other types of models. 
Given that the optimal policy for a decision depends on all the variables known when making it, 
the complexity of these algorithms grows exponentially with the horizon for MIDs containing 
temporal decisions, while it grows only linearly when all the decisions are atemporal. For this 
reason the MIDs presented in this paper and those available at 
www.probmodelxml.org/networks only have atemporal decisions; all of them can be evaluated 
with OpenMarkov in less than 10 seconds. 
 
Figure 11. Temporal evolution of different variables in the HIV model. a) Probability of each state of the 
variable State for combination therapy.  b) Probability that the patient is alive, given by the sum of the 
probabilities of the states A, B and C of the variable State.  c) Instantaneous value of Cost of drug, with 
3.5% discount.  d) Cumulative value of Life years, with 3.5% discount. 
                                                     
e
 A minor modification is necessary, however, for the efficiency of that algorithm: value nodes should be 
kept separate until the moment of eliminating the first decision, because if we joined them into a single 
node when initializing the algorithm, the computational complexity would grow exponentially with the 
horizon. 
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5 Comparison of MIDs with other representation techniques 
5.1 MIDs vs. spreadsheet models 
The most common tool for implementing state-transition models is Excel, at least in Europe,11 
probably because this program is available in almost all computers, which avoids the need to 
buy dedicated software, and because it is relatively easy to write formulae in Excel. However, 
the more complex the model, the more Excel skills are needed, and sensitivity analysis is 
usually implemented by Visual Basic macros, which requires some knowledge of programming. 
For a modeller, the main drawback is the need to encode the logic of the model in the form of 
sheets and formulae, which cannot be reused from other models. Additionally, in Excel models 
the state must be represented by a single variable because spreadsheets cannot deal with 
PXOWLGLPHQVLRQDOPDWULFHVLQDQDWXUDOZD\7KHRQO\SRVVLELOLW\RIUHSUHVHQWLQJWKHSDWLHQW¶V
history is to subdivide the states, as explained in Section 3.2 (Figure 7 and 9), and the more 
states in the model, the more difficult it is to build and maintain it. For this reason, when 
Hawkins et al.18 built a Markov model for the treatment of epilepsy, which needed to keep track 
of the time spent in the current state, they used R instead of Excel. In contrast, MIDs can 
UHSUHVHQWWKHSDWLHQW¶VKLVWRU\ZLWKRQHRUVHYHUDOPHPRU\YDULDEOHVZLWKRXWPXOWLSO\LQJWKH
number of states.  
The problem of Excel models is not only the effort required to write the formulae, but also the 
difficulty of uncovering the possible mistakes, because those formulae are more difficult to 
understand and debug than a piece of code written in a programming language. In fact, we 
detected minor bugs in four of the five Excel models that we translated into MIDs, even though 
their authors were in general experienced decision analysts. Fortunately, the impact of those 
bugs was irrelevant, but in other fields of scientific research there are notorious examples of 
Excel bugs that led to wrong conclusions.19-21 ,QFRQWUDVW2SHQ0DUNRY¶VFRGHLVSHULRGLFDOO\
tested using modern software-engineering techniques and tools, and the probability that the 
modeller makes a mistake when building a model with a graphical user interface is much 
smaller than when writing formulae and macros that mingle the model with the inference 
algorithm. 
For an evaluation agency, the main advantage of a model implemented as a spreadsheet is that 
the same file contains the model, the code and all the numerical results of its evaluation, thus 
making it possible to trace its execution step by step. However, the presence of complex 
formulae and Visual Basic macros makes it difficult to understand all the details of a model and 
check its correctness. In fact, even though we had examined thoroughly the five Excel models 
when translating them into MIDs, we only discovered the bugs when comparing the numeric 
outputs of both versions of each model. As Drummond Rennie said,22 ³+LOOHWDO23 showed that 
it takes specially trained experts working whole time about two weeks to review CEAs provided 
by industry, even though these experts have all the information and have spreadsheets already in 
place. We agree with them that journal peer reviewers cannot possibly identify all the many 
serious problems, given their part-time approach.´In contrast, MIDs are more transparent than 
spreadsheets because their causal graphs clearly show the structural assumptions and because 
the model can be inspected without reading a single line of code.   
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5.2 MIDs vs. Markov decision trees 
Both decision trees and IDs, as well as their Markov extensions, are based on graphs containing 
three types of nodes: chance, decision and value; Markov decision trees have a fourth type of 
node, called Markov node. The main difference is that in (Markov) decision trees the links 
outgoing from a node represent the states of the corresponding variable, while links in IDs and 
MIDs represent causal relations. In general every variable appears several times in a decision 
tree, and the number of branches grows exponentially with the number of variables, which 
makes (Markov) decision trees inadequate for building large models. In contrast, in an MID 
each variable can appear at most twice (once for each of the first two cycles), and it is therefore 
much more compact than the equivalent Markov decision tree, in the same way as every ID is 
much more compact than the equivalent decision tree. The reader can appreciate the difference 
by trying to mentally build a Markov decision tree for the MIDs in Figure 5 and 6. For this 
reason, (M)IDs can solve much larger problems than (Markov) decision trees. 
Additionally, when the dynamics of a model depends RQWKHSDWLHQW¶VKLVWRU\Markov decision 
trees have only two possibilities: to multiply the number of states, as in Figure 7 and 9, or to use 
so-called tracker variables. The first option leads to cumbersome models, just as when using 
Excel. The second requires patient-level simulation to evaluate the model, which often takes 
much longer than cohort analysis. In contrast, many MIDs containing memory variables, 
including all the examples shown in this paper, can be efficiently evaluated with the algorithm 
by Arias and Díez.6 Additionally, (M)IDs containing more than one decision are equivalent to 
(Markov) decision trees with embedded decision nodes, which cannot be evaluated with 
standard algorithms.3 These are other reasons for which Markov decision trees are inadequate 
for large problems.  
With respect to software tools, the main package for building (Markov) decision trees and 
performing cost-effectiveness analysis is TreeAge Pro, a mature commercial product. Older 
programs, such as WinDM and SMLTREE, are no longer available. OpenMarkov, in contrast, is 
still a research prototype, but in addition to supporting MIDs and other types of probabilistic 
graphical models, has the key advantage of being open-source, which implies that it can be used 
for free, and also that its code can be LQVSHFWHGDQGH[WHQGHGWRDGGUHVVWKHXVHU¶VQHHGV
Currently TreeAge Pro offers many features not available in OpenMarkov, but the latter has 
more and more features not available in the former. 
5.3 MIDs vs. programming languages 
Some state-transition models for cost-effectiveness analysis have been implemented in C++, 
MATLAB, R or a language in the BUGS family, such as WinBUGS, OpenBUGS or JAGS. The 
main advantage of this approach is the possibility of implementing virtually any model and any 
evaluation algorithm. The drawback is that, as in the case of Excel, the model is mingled with 
the algorithm and everything must be programmed by the decision analyst, from the 
combination of transition probabilities to the sensitivity analysis and the graphical display of 
results. 
In contrast, building, debugging and evaluating an MID with OpenMarkov is much faster and 
easier but, as mentioned above, some models may contain features that are not yet available in 
this package, thus making it necessary to use a different modelling tool. 
 14 
 
From the point of view of an evaluation agency, assessing the validity of a model encoded as a 
computer program may be difficult, especially if the code lacks a good design, clear in-line 
comments and sufficient additional documentation.  
Finally, we should mention that BUGS is especially suited for health technology assessment 
based on clinical trials because of its ability to integrate statistical inference and cost-
effectiveness analysis, but building and evaluating a model is much harder than when using 
OpenMarkov. We have begun researching the integration of these tools, in order to combine the 
statistical power of the former with the facilities for model building and analysis of the latter; 
our goal is to use OpenMarkov to build the model, estimate its parameters from data (by 
connecting to some of the software packages in the BUGS family) and then perform cost-
effectiveness and sensitivity analysis with the graphical user interface, without writing any 
code.  
5.4 MIDs vs. discrete event simulations 
Discrete event simulation (DES) is commonly used to model many entities that interact between 
them and with the environment;24 for example, several individuals that can transmit an 
infectious disease to one another, or several beds in an emergency service to be occupied by 
patients who arrive randomly.  
In the field of economic evaluation, some experts have argued that when a problem involves 
numeric variables or requires several variables to model the evolution of the patient DES is 
more appropriate than a state-transition model.24-29 However, we have shown that MIDs can 
easily address those problems without abandoning the paradigm of state-transition models. 
Additionally, many MIDs²including all those mentioned in this paper²can be evaluated with 
cohort analysis, which is in many cases more efficient than patient-level simulation.  
The main limitation of MIDs is the assumption of discrete time, while in DES time can be either 
discrete or continuous, but it is unlikely that this difference may affect the conclusions of an 
economic evaluation.24 
In summary, some problems that were previously supposed to require DES can be analysed with 
MIDs, thus maintaining all the advantages of state-transition models, which, according to a 
panel of experts, ³may be simple to develop, debug, communicate, and analyze, and they readily 
DFFRPPRGDWHWKHHYDOXDWLRQRISDUDPHWHUXQFHUWDLQW\´.30  
6 Conclusions  
Markov influence diagrams (MIDs) are a new type of probabilistic graphical model especially 
designed for cost-effectiveness analysis with state-transition models. They extend influence 
diagrams in the same way as Markov decision trees extend decision trees. 
We have argued that most state-transition models implemented as spreadsheets or Markov 
decision trees can be built much more easily using MIDs. In particular, MIDs can use memory 
variables WRVXPPDULVHWKHSDWLHQW¶VKLVWRU\without multiplying the number of states.  
In addition to using several variables to model the evolution of the patient, MIDs can also 
combine numeric and categorical variables in the same model, which are two of the advantages 
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of DES. Therefore MIDs can implement complex models that by far exceed the expressive 
power of spreadsheets without abandoning the paradigm of state-transition models, in which 
many health economists feel more comfortable. 
For a decision analyst, building an MID and evaluating it with OpenMarkov is much easier and 
faster than implementing it as a spreadsheet, a Markov decision tree or a computer program, 
especially because its graphical user interface saves a lot of time and reduces the probability of 
making mistakes. Additionally, MIDs containing several decisions, such as the example in 
Figure 6, can be evaluated with the algorithm by Arias and Díez,8 which is difficult to 
implement in R or in another programming language, and virtually impossible in Excel or in 
patient-level simulation. However, there are other types of problems for which DES or dynamic 
transmission models are more adequate. 
For an evaluation agency, understanding and assessing the correctness of an MID is much easier 
than for other types of models, for two reasons: because every MID is based on a causal graph 
that summarises the structure of the model, and because it can be inspected separately from the 
software code used to evaluate it. 
Most of the advantages of MIDs depend on the availability of software with a graphical user 
interface for building and evaluating them. The only one currently available is OpenMarkov, an 
open-source package. Therefore in practice the applicability of MIDs is limited by the facilities 
offered by this tool, which is still a research prototype. It already offers a wide range of 
potentials²including, for example, Weibull distributions and generalised linear models with 
fractional polynomials²and several types of deterministic and probabilistic sensitivity analysis; 
but if a problem required a feature not available in this tool, it would be impossible to build the 
model as an MID until that option is available. However, new features are constantly added to 
OpenMarkov, and other software packages might support MIDs in the future. 
Acknowledgements 
F.J.D., M.Y. and I.B. spent three months each at the Centre for Health Economics of the 
University of York, invited by Prof. Mark Sculpher. We thank him, Marta Soares and Claire 
Rothery for many comments and suggestions about this manuscript, and Susan Griffin, Paul 
Revill, Máirín Ryan, Quentin Summerfield and Simon Walker for sharing their models with us.  
I.B. received a predoctoral grant from UNED. J.P. was financed by MED-EL GmbH and by a 
predoctoral FPU grant of the Ministry of Education, Science and Sport. The stays at the 
University of York were financed by a Santander Bank±UNED mobility grant (F.J.D.), the 
Ministry of Science and Technology (M.Y.) and UNED (I.B.). Our work was supported by the 
Spanish Ministry of Education and Science (grant TIN2006-11152), the Ministry of Science and 
Technology (TIN2009-09158), FONCICYT (no. 95185), the 7th Frame Programme (no. 262266 
and FP7-PEOPLE-2012-IAPP-324401), the Health Institute Carlos III of the Spanish 
Government (PI13/02446) and the European Regional Development Fund. 
 16 
 
References 
1. Raiffa H. Decision Analysis. Introductory Lectures on Choices under Uncertainty. Reading, 
MA: Addison-Wesley; 1968. 
2. Howard RA, Matheson JE. Influence diagrams. In: R. A. Howard, J. E. Matheson, eds. 
Readings on the Principles and Applications of Decision Analysis. Menlo Park, CA: 
Strategic Decisions Group; 1984:719-762. 
3. Arias M, Díez FJ. The problem of embedded decision nodes in cost-effectiveness decision 
trees. Pharmacoeconomics 2014;32:1141-1145. 
4. Kuntz KM, Weinstein MC. Modelling in Economic Evaluation. In: Drummond MF, McGuire 
A, eds. Economic Evaluation in Health Care. New York: Oxford University Press; 
2001:141-171. 
5. Arias M, Díez FJ. Cost-effectiveness analysis with sequential decisions. Technical report 
CISIAD-11-01. Madrid: UNED; 2011. 
6. Arias M, Díez FJ. Cost-effectiveness analysis with influence diagrams. Methods of 
Information in Medicine 2015;54:353-358. 
7. Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. New 
York: Oxford University Press; 2006. 
8. Gray AM, Clarke PM, Wolstenholme J, Wordsworth S. Applied Methods of Cost-
Effectiveness Analysis in Healthcare. New York: Oxford University Press; 2011. 
9. Siebert U, Alagoz O, Bayoumi A, et al. State-transition modeling: A report of the ISPOR-
SMDM Modeling Good Research Practices Task Force-3. Medical Decision Making 
2012;32:690-700. 
10. Sonnenberg FA, Beck JR. Markov models in medical decision making: A practical guide. 
Medical Decision Making 1993;13:322-339. 
11. Tosh J, Wailoo A. Review of software for decision modelling. Sheffield, UK: University of 
Sheffield; 2008. 
12. Chancellor JV, Hill AM, Sabin CA, Simpson KN, Youle M. Modelling the cost 
effectiveness of lamivudine/zidovudine combination therapy in HIV infection. 
Pharmacoeconomics 1997;12:54-66. 
13. Callejo D, Lopez-Polin A, Blasco J. Cost utility of human papilloma virus vaccine in Spain. 
Value in Health. 2010;13:A258-A258. 
14. Walker S, Girardin F, McKenna C, et al. Cost-effectiveness of cardiovascular magnetic 
resonance in the diagnosis of coronary heart disease: An economic evaluation using data 
from the CE-MARC study. Heart 2013;99:873. 
15. Díez FJ, Druzdzel MJ. Canonical probabilistic models for knowledge engineering. 
Technical report CISIAD-06-01. Madrid: UNED; 2006. 
16. Arias M, Díez FJ, Palacios-Alonso MA, Bermejo I. ProbModelXML. A format for encoding 
probabilistic graphical models. Technical report CISIAD-11-02. Madrid: UNED; 2011. 
17. Luque M, Díez FJ. Variable elimination for influence diagrams with super-value nodes. 
International Journal of Approximate Reasoning 2010;51:615-631. 
18. Hawkins N, Sculpher M, Epstein D. Cost-effectiveness analysis of treatments for chronic 
disease: Using R to incorporate time dependency of treatment response. Medical Decision 
Making 2005;25:511-519. 
 17 
 
19. Baggerly KA, Coombes KR. Deriving chemosensitivity from cell lines: Forensic 
bioinformatics and reproducible research in high-throughput biology. Annals of Applied 
Statistics 2009;3:1309-1334. 
20. Herndon T, Ash M, Pollin R. Does high public debt consistently stifle economic growth? A 
critique of Reinhart and Rogoff. Cambridge Journal of Economics 2013;38:257-279. 
21. Reinhart C, Rogoff K. Reinhart, Rogoff admit Excel mistake, rebut other critiques. Wall 
Street Journal Apr 17 2013. 
22. Rennie D. Cost-effectiveness analyses: Making a pseudoscience legitimate. Journal of 
Health Politics, Policy and Law 2001;26:383-386. 
23. Hill S, Mitchell A, Henry D. Problems with the interpretation of pharmacoeconomic 
analyses - A review of submissions to the Australian pharmaceutical benefits scheme. 
JAMA. 2000;283:2116-2121. 
24. Karnon J. Alternative decision modelling techniques for the evaluation of health care 
technologies: Markov processes versus discrete event simulation. Health Economics 
2003;12:837-848. 
25. Davies R. An assessment of models of a health system. Journal of the Operational Research 
Society 1985;36:679-687. 
26. Siebert U. When should decision-analytic modeling be used in the economic evaluation of 
health care? European Journal of Health Economics 2003;4:143-150. 
27. Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 
2005;23:323-332. 
28. Caro JJ, Getsios D, Möller J. Regarding probabilistic analysis and computationally 
expensive models: Necessary and required? Value in Health 2007;10:317-318. 
29. Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research Practices²Overview: 
A report of the ISPOR-SMDM Modeling Good Research Practices Task Force±1. Medical 
Decision Making. 2012;32(5):667-677. 
30. Roberts M, Russell LB, Paltiel AD, et al. Conceptualizing a model: A report of the ISPOR-
SMDM Modeling Good Research Practices Task Force±2. Medical Decision Making 
2012;32:678-689. 
31. Hazen GB. Dynamic influence diagrams: Applications to medical decision modeling. In: 
Brandeau ML, et al., eds. Operations Research and Health Care. Boston, MA: Kluwer 
Academic Publishers; 2004:613-638. 
  
